迈普医学, the first company to adopt the second set of listing standards, is about to be listed on the Growth Enterprise Market

On July 5th, Guangzhou MaiPu Regenerative Medical Technology Co., Ltd. (hereinafter referred to as “MaiPu Medical”) publicly released the “Prospectus for Initial Public Offering of Stocks and Listing on the Growth Enterprise Market”, signifying that the first company in the entire market to apply for and complete registration for listing under the second set of listing standards of the Growth Enterprise Market is entering the issuance process and is about to be listed on the Growth Enterprise Market.AnnouncementThis means that the first company in the entire market to apply for and complete registration under the second set of listing standards for the Growth Enterprise Market is entering the issuance process and is about to be listed on the Growth Enterprise Market.

　　It is understood that after the reform of the registration system for the Growth Enterprise Market, the listing conditions have been optimized, comprehensively considering the estimated market value, revenue,net profitand other indicators, formulating diversified listing conditions to support innovative and entrepreneurial enterprises at different growth stages and of different types to be listed on the Growth Enterprise Market. On June 9th, MaiPu Medical officially obtained the registration approval document from the China Securities Regulatory Commission, becoming the first company in the entire market to apply for and complete registration under the second set of listing standards of the Growth Enterprise Market (i.e., “estimated market value not less than 1 billion yuan, net profit positive in the most recent year, andoperating revenuenot less than 100 million yuan”)

　　The successful registration of MaiPu Medical’s listing on the Growth Enterprise Market benefits from the registration system’s concept centered on information disclosure and the inclusiveness of the stock listing system, reflecting the registration system reform’s support for growth-oriented innovative and entrepreneurial enterprises.

　　The prospectus shows that MaiPu Medical is a high-tech enterprise dedicated to combining the characteristics of artificially synthesized materials, utilizing advanced manufacturing technologies, and developing high-performance implantable medical devices. Since its establishment, MaiPu Medical has envisioned “becoming a world-leading enterprise in the field of implantable medical devices, providing excellent products, and serving global patients”. It is the only enterprise in the domestic neurosurgery field that simultaneously possesses implantable medical device products such as artificial dura mater patches, craniomaxillofacial repair products, and absorbable hemostatic gauze. It covers the key implantable medical devices needed for craniotomy. MaiPu Medical is also clinically needs-oriented, giving full play to the advantages of multiple technology platforms and expanding product applications to multiple departments.

　　As of the end of 2020, MaiPu Medical has 156 authorized domestic patents and 21 overseas patents, including 87 invention patents; 106 domestic patent applications that have been accepted but not yet authorized, and 11 overseas patent applications, including 109 invention patent applications.

　　In terms of product innovation, the company’s artificial dura mater project won the “China Industry Award Nomination Award”, one of three medical device companies to win that year; the invention patent “A Bioactive Artificial Dura Mater and Its Preparation Method” won the “China Patent Excellence Award”; the core achievement, the absorbable dura mater patch, is the first domestic product of its kind to industrialize using bio-additive manufacturing technology, and is included in the Ministry of Science and Technology of China’s “Innovative MedicalDevice Product Catalog (2018)”, the only dural product in the catalog and one of only nine “internationally original” products. The craniomaxillofacial repair product is one of the few domestic products based on PEEK material and used for craniomaxillofacial defect repair. The absorbable hemostatic gauze is a high-performance hemostatic product specifically developed for the hemostasis needs of neurosurgery, and its industrialization is expected to break the long-term import monopoly of absorbable hemostatic products in China’s neurosurgery field.

　　At the same time, MaiPu Medical’s independently developedhigh-throughputelectrospinning equipment is one of the important research and development achievements of the National High-Tech Research and Development Plan (863 Program) in 2015, and the invention patent “An Electrospinning Machine” won the “China Patent Silver Award”; the independently developed “Lepu” series of bio-3D printers can be used for cutting-edge scientific and clinical application research such as in vitro tissue models or in vivo tissue construction, and has passed tests in compliance with EU EMC, LVD, RoHS directives and US FCC directives.

　　According to the latest publicly available information, MaiPu Medical has been approved to register 3 Class III and 1 Class II medical device products, and has filed 1 Class I medical device product, obtained CE certificates and CE Design certificates for 4 products, and has 9 products under development, laying the foundation for the continued growth of future operations’Achievementsin the future.

　　Currently, MaiPu Medical has become one of the few domestic neurosurgical high-performance implantable medical device manufacturers with the capacity for large-scale export to overseas high-end medical markets. Data shows that the company has established good cooperative relationships with more than 500 distributors at home and abroad, its products have entered more than 800 hospitals in China, and the international market covers more than 70 countries and regions in Europe, South America, Asia, and Africa, with more than 200,000 clinical applications of its products, completing the construction of a global marketing system centered on product registration, promotion and sales, and After-sale Service.